Targeted therapy in Tel Aviv typically costs from $7,200 to $16,800. The final expense depends on the specific drug regimen, the clinical stage of the tumor, and the necessary genomic profiling. Patients save around 64% compared to the US, where this procedure costs $40,000 on average. Inclusions often cover hospital stays, multidisciplinary planning, and transfers to the clinic.
- Lutetium-177 therapy: $13,800 to $18,900 for targeted radionuclide treatment.
- Drug licensing: Patented monoclonal antibodies frequently add a premium to the base administration cost.
- Facility type: Private centers like Assuta Medical Center often charge more than public institutions.
- Treatment cycles: Totals vary based on the number of infusions required for the protocol.
Bookimed Expert Insight: Tel Aviv hosts more Newsweek-ranked oncology departments than any other city in Israel. This concentration of expertise allows for highly specific protocols, such as KADCYLA therapy for breast cancer. Clinics like Sourasky Medical Center (Ichilov) serve as JCI-accredited hubs where patients access Oxford-trained specialists. These doctors often lead national genomic medicine initiatives, providing access to clinical trials not available elsewhere.